209 related articles for article (PubMed ID: 10935213)
21. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.
Ungureanu A; Le Garff-Tavernier M; Costopoulos M; Parratte T; Brinet A; Durand H; Gaultier C; Hurstel R; Alamome I; Sellal F; Ahle G
J Neurol; 2021 Aug; 268(8):2890-2894. PubMed ID: 33609156
[TBL] [Abstract][Full Text] [Related]
22. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.
Strehlow F; Bauer S; Martus P; Weller M; Roth P; Schlegel U; Seidel S; Scheibenbogen C; Korfel A; Kreher S
J Neurooncol; 2016 Aug; 129(1):165-71. PubMed ID: 27294357
[TBL] [Abstract][Full Text] [Related]
23. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
Baraniskin A; Kuhnhenn J; Schlegel U; Chan A; Deckert M; Gold R; Maghnouj A; Zöllner H; Reinacher-Schick A; Schmiegel W; Hahn SA; Schroers R
Blood; 2011 Mar; 117(11):3140-6. PubMed ID: 21200023
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal Fluid Level of Soluble CD27 Is Associated with Disease Severity in Neuromyelitis Optica Spectrum Disorder.
Liu B; Zhong X; Lu Z; Qiu W; Hu X; Wang H
Neuroimmunomodulation; 2018; 25(4):185-192. PubMed ID: 30423585
[TBL] [Abstract][Full Text] [Related]
25. Measurement and cellular sources of the soluble interleukin-2 receptor in primary central nervous system lymphoma.
Kitai R; Sasaki H; Matsuda K; Tsunetoshi K; Yamauchi T; Neishi H; Matsumura K; Tsunoda A; Takeuchi H; Sato K; Kikuta K
Brain Tumor Pathol; 2013 Jan; 30(1):34-9. PubMed ID: 22399193
[TBL] [Abstract][Full Text] [Related]
26. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma.
Whitcup SM; Stark-Vancs V; Wittes RE; Solomon D; Podgor MJ; Nussenblatt RB; Chan CC
Arch Ophthalmol; 1997 Sep; 115(9):1157-60. PubMed ID: 9298057
[TBL] [Abstract][Full Text] [Related]
27. Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies.
van den Bent MJ; Lamers CH; van 't Veer MB; Sillevis Smitt PA; Bolhuis RL; Gratama JW
Ann Hematol; 2002 Apr; 81(4):187-91. PubMed ID: 11976819
[TBL] [Abstract][Full Text] [Related]
28. Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis.
Kara IO; Sahin B; Gunesacar R
Adv Ther; 2007; 24(1):29-40. PubMed ID: 17526459
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
30. CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma.
Ikeguchi R; Shimizu Y; Shimizu S; Kitagawa K
Mult Scler; 2018 Aug; 24(9):1212-1223. PubMed ID: 28657431
[TBL] [Abstract][Full Text] [Related]
31. Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease.
Feresiadou A; Nilsson K; Ingelsson M; Press R; Kmezic I; Nygren I; Svenningsson A; Niemelä V; Gordh T; Cunningham J; Kultima K; Larsson A; Burman J
J Neuroimmunol; 2019 Jul; 332():31-36. PubMed ID: 30928869
[TBL] [Abstract][Full Text] [Related]
32. CXCL13 and CXCL12 in central nervous system lymphoma patients.
Fischer L; Korfel A; Pfeiffer S; Kiewe P; Volk HD; Cakiroglu H; Widmann T; Thiel E
Clin Cancer Res; 2009 Oct; 15(19):5968-73. PubMed ID: 19773382
[TBL] [Abstract][Full Text] [Related]
33. Low levels of specific T cell activation marker CD27 accompanied by elevated levels of markers for non-specific immune activation in the cerebrospinal fluid of patients with AIDS dementia complex.
Portegies P; Godfried MH; Hintzen RQ; Stam J; van der Poll T; Bakker M; van Deventer SJ; van Lier RA; Goudsmit J
J Neuroimmunol; 1993; 48(2):241-7. PubMed ID: 8227320
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma.
Baraniskin A; Kuhnhenn J; Schlegel U; Schmiegel W; Hahn S; Schroers R
J Neurooncol; 2012 Sep; 109(2):239-44. PubMed ID: 22729947
[TBL] [Abstract][Full Text] [Related]
35. High Serum Soluble CD27 Level Correlates with Poor Performance Status and Reduced Survival in Patients with Advanced Lung Cancer.
Kashima J; Okuma Y; Hosomi Y; Hishima T
Oncology; 2019; 97(6):365-372. PubMed ID: 31533124
[TBL] [Abstract][Full Text] [Related]
36. T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
Wong YYM; van der Vuurst de Vries RM; van Pelt ED; Ketelslegers IA; Melief MJ; Wierenga AF; Catsman-Berrevoets CE; Neuteboom RF; Hintzen RQ
Mult Scler; 2018 Nov; 24(13):1715-1724. PubMed ID: 30019626
[TBL] [Abstract][Full Text] [Related]
37. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients.
Hintzen RQ; van Lier RA; Kuijpers KC; Baars PA; Schaasberg W; Lucas CJ; Polman CH
J Neuroimmunol; 1991 Dec; 35(1-3):211-7. PubMed ID: 1659587
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic significance of soluble c-kit in the cerebrospinal fluid of patients with germ cell tumors.
Miyanohara O; Takeshima H; Kaji M; Hirano H; Sawamura Y; Kochi M; Kuratsu J
J Neurosurg; 2002 Jul; 97(1):177-83. PubMed ID: 12134909
[TBL] [Abstract][Full Text] [Related]
40. Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy.
Nagato T; Komatsuda H; Hayashi R; Takahara M; Kishibe K; Yasuda S; Yajima Y; Kosaka A; Ohkuri T; Oikawa K; Harabuchi S; Kono M; Yamaki H; Wakisaka R; Hirata-Nozaki Y; Ohara K; Kumai T; Katada A; Hayashi T; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2023 Jul; 72(7):2087-2098. PubMed ID: 36811663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
